Skip to Content

Chlorpheniramine / Codeine / Pseudoephedrine Dosage

Applies to the following strength(s): 2 mg-10 mg-30 mg/5 mL ; 2 mg-8 mg-30 mg/5 mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Cold Symptoms

Chlorpheniramine 2 mg/codeine 10 mg/pseudoephedrine 30 mg per 5 mL oral liquid:
10 mL orally every 4 hours as needed; not to exceed 4 doses in 24 hours

Chlorpheniramine 2 mg/codeine 8 mg/pseudoephedrine 30 mg per 5 mL oral liquid:
10 mL orally every 4 to 6 hours as needed; not to exceed 40 mL in 24 hours

Comments:
-Liquid preparations should be measured with an accurate milliliter measuring device.

Uses: For the temporary relief symptoms due to the common cold, hay fever (allergic rhinitis), or other upper respiratory allergies.

Usual Pediatric Dose for Cold Symptoms

Under 12 years: Not recommended

Age: 12 years or older:
-Chlorpheniramine 2 mg/codeine 10 mg/pseudoephedrine 30 mg per 5 mL oral liquid: 10 mL orally every 4 hours as needed
-Chlorpheniramine 2 mg/codeine 8 mg/pseudoephedrine 30 mg per 5 mL oral liquid: 10 mL orally every 4 to 6 hours as needed
Maximum dose: 40 mL in 24 hours

Comments:
-Liquid preparations should be measured with an accurate milliliter measuring device.
-Codeine should not be used in adolescents who are obese or have conditions such as sleep apnea or severe lung disease which may increase the risk of serious breathing problems.

Uses: For the temporary relief symptoms due to the common cold, hay fever (allergic rhinitis), or other upper respiratory allergies.

Renal Dose Adjustments

Use with caution, especially in patients with severe renal impairment

Liver Dose Adjustments

Use with caution, especially in patients with severe renal impairment

Precautions

The US FDA has issued a Drug Safety Communication restricting use of prescription codeine pain and cough medicines in children less than 12 years. This update follows previous communications evaluating the potential risks of codeine. Children less than 12 years appear to be at the greatest risk of codeine associated serious adverse events including slowed or difficult breathing and death. The FDA is considering additional regulatory action for over the counter (OTC) combination cough and cold products containing codeine. At this time, it appears prudent to avoid codeine use in all children less than 12 years and avoid use in adolescents between 12 and 18 years who are obese, or have conditions such as obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems.

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule V

Dialysis

Data not available

Other Comments

Administration advice:
-Take orally with or without food
-Oral measuring devices should be provided to ensure accuracy in dosing

Storage requirements:
-Protect from moisture and light

General:
-Patients who are ultra-rapid metabolizers of codeine due to a CYP450 2D6 polymorphism, will convert codeine more rapidly and completely to morphine resulting in unexpectedly high morphine levels, which may be life-threatening.
-Codeine use is contraindicated in the postoperative period in children who have undergone tonsillectomy and/or adenoidectomy.
-Professional organizations are concerned with use of all cough and cold medicines in children; prescription and non-prescription alternatives to codeine for cough also have risks.

Monitoring:
-Cardiovascular: Monitor for signs of hypotension, especially in those whose blood pressure is compromised
-Respiratory: Monitor for respiratory depression
-Gastrointestinal: Monitor for constipation and decreased bowel motility in post-operative patients.
-Patients should be monitored for the development of addiction, abuse, or misuse.
with their healthcare provider regarding concomitant use of other CNS depressants.

Patient advice:
-Patients should understand that codeine use can result in addiction, abuse, and misuse; recommended doses should not be exceeded.
-Patients should be understand that this product is for temporary relief of cough; if cough persists for longer than 1 week, recurs, or is accompanied by fever, rash, or persistent headache, a health care professional should be consulted.
-Patients should understand risks of life-threatening respiratory depression and when this risk is greatest; patients should be aware that a genetic mutation may result in greater codeine toxicity in some patients; breastfed infants of women who have this genetic mutation are also at risk.
-Women who are breastfeeding, pregnant, or planning to become pregnant should speak to their healthcare provider before using this product.
-This drug may cause drowsiness, dizziness, or impair thinking or motor skills; patients should avoid driving or operating machinery while taking this drug.
-Concomitant use of alcohol, sedatives, and tranquillizers may increase drowsiness; patients should avoid alcohol and consult with their healthcare provider regarding concomitant use of other CNS depressants.
-Pseudoephedrine may cause sleeplessness, especially if it is taken up to several hours before going to bed.

Hide